S100A7 and neoplasm: Additionally, in the study “A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer”) (Cai Y. et al., 2023), bladder cancer patients were divided into two heterogeneous metabolic subtypes (MRSs): MRS1, characterized by inactive metabolic features but with an immune-infiltrated microenvironment; MRS2, characterized by upregulated lipid metabolism.